CN113473993B - 治疗运动神经元疾病的方法和组合物 - Google Patents

治疗运动神经元疾病的方法和组合物 Download PDF

Info

Publication number
CN113473993B
CN113473993B CN202080017084.3A CN202080017084A CN113473993B CN 113473993 B CN113473993 B CN 113473993B CN 202080017084 A CN202080017084 A CN 202080017084A CN 113473993 B CN113473993 B CN 113473993B
Authority
CN
China
Prior art keywords
ibudilast
pterostilbene
nicotinamide riboside
pharmaceutically acceptable
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080017084.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113473993A (zh
Inventor
J·M·埃斯特雷拉阿里盖尔
M·E·奥夫拉多尔帕拉
R·萨尔瓦多
R·W·德林格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Valencia
Elysium Health Inc
Original Assignee
University of Valencia
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Valencia, Elysium Health Inc filed Critical University of Valencia
Publication of CN113473993A publication Critical patent/CN113473993A/zh
Application granted granted Critical
Publication of CN113473993B publication Critical patent/CN113473993B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080017084.3A 2019-02-26 2020-02-25 治疗运动神经元疾病的方法和组合物 Active CN113473993B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810728P 2019-02-26 2019-02-26
US62/810,728 2019-02-26
US201962892754P 2019-08-28 2019-08-28
US62/892,754 2019-08-28
PCT/US2020/019600 WO2020176445A1 (en) 2019-02-26 2020-02-25 Methods and compositions for treating motor neuron diseases

Publications (2)

Publication Number Publication Date
CN113473993A CN113473993A (zh) 2021-10-01
CN113473993B true CN113473993B (zh) 2024-06-04

Family

ID=72239986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017084.3A Active CN113473993B (zh) 2019-02-26 2020-02-25 治疗运动神经元疾病的方法和组合物

Country Status (5)

Country Link
US (1) US12350283B2 (enExample)
EP (1) EP3930728A1 (enExample)
JP (1) JP7580380B2 (enExample)
CN (1) CN113473993B (enExample)
WO (1) WO2020176445A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009529A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2018039207A1 (en) * 2016-08-22 2018-03-01 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
CN107849083A (zh) * 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
WO2018213420A1 (en) * 2017-05-17 2018-11-22 Universitat De Valencia-Estudi General Treating and preventing motor neuron diseases using nicotinamide riboside

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219552A1 (en) * 2001-08-14 2004-11-04 Ali Ait Ikhlef Novel molecular target for neurotoxicity
EP3429354A4 (en) * 2016-03-16 2020-03-25 Chromadex Inc. B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US11286274B2 (en) * 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009529A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CN107849083A (zh) * 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法
WO2018039207A1 (en) * 2016-08-22 2018-03-01 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
WO2018213420A1 (en) * 2017-05-17 2018-11-22 Universitat De Valencia-Estudi General Treating and preventing motor neuron diseases using nicotinamide riboside

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis;O A Andreassen等;《Neuroreport》;第11卷(第11期);摘要部分 *
O A Andreassen等.N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis.《Neuroreport》.2000,第11卷(第11期),摘要部分. *
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study;Ryan W Dellinger等;《NPJ Aging Mech Dis》;20171124;第1-9页 *
异丁司特的临床安全性及体内药物浓度研究;张伟等;《海峡药学》;20130430;第25卷(第04期);277-279 *
新药研究与开发;黄世杰;《国际药学研究杂志》;第44卷(第1期);81 *
黄世杰.新药研究与开发.《国际药学研究杂志》.2017,第44卷(第1期),81. *

Also Published As

Publication number Publication date
CN113473993A (zh) 2021-10-01
WO2020176445A1 (en) 2020-09-03
EP3930728A1 (en) 2022-01-05
JP7580380B2 (ja) 2024-11-11
JP2022524930A (ja) 2022-05-11
US12350283B2 (en) 2025-07-08
US20220160745A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CN113244396A (zh) 靶向nad+以治疗化学和放射疗法引发的认知损害、神经病变和不活动
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
KR101951220B1 (ko) 조합 als 치료법
CN111032027B (zh) 使用烟酰胺核糖核苷治疗和预防运动神经元疾病
TW202227082A (zh) 用於治療癌症之組合療法
US20210128593A1 (en) Synergistic nutritional neuroprotective compositions for ameliorating neural dysfunction
JP7580380B2 (ja) 運動ニューロン疾患を処置するための方法及び組成物
AU2021365138A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
US20230381121A1 (en) N-palmitoylethanolamide and melatonin for use in the treatment of autism spectrum disorder and other neurobehavioral disorders similarly accompanied by restlessness, irritability, sleep disorders, and potentially stereotypies
CA2372850C (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
EP2150253B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
EP2244702B1 (en) Treatment of neural diseases or conditions
EP3609487A1 (en) Compositions and methods that attenuate cognitive aging in individuals who do not have dementia
US20230104124A1 (en) N-palmitoylethanolamide and docosahexaenoic acid for use in the treatment of autism spectrum disorder and other depressive syndromes
WO2026102345A1 (en) Methods of administering the voltage-gated potassium channel opener azetukalner
HK1241697B (en) Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis
HK1241697A1 (en) Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant